Market Place
Sourcing Support
Fujirebio Acquires PSG to Boost Life Science Capabilities
23 Jun 2025 //
BUSINESSWIRE
Fujirebio, Stanford Partner to Advance Infectiou Disease Research
05 Jun 2025 //
BUSINESSWIRE
Fujirebio launches Lumipulse G sTREM2 Assay for Research
04 Jun 2025 //
BUSINESSWIRE
Fujirebio`s Alzheimer`s Plasma Test Gets Market Clearance
17 May 2025 //
BUSINESSWIRE
Ari Bio and Fujirebio Complete Set for Alzheimer`s Biomarker
09 May 2025 //
BUSINESSWIRE
Fujirebio Submits FDA Filing For Alzheimer`s Diagnostic Test
25 Sep 2024 //
BUSINESSWIRE
AriBio And Fujirebio Advance Alzheimer`s Biomarker Development
15 Jul 2024 //
BUSINESSWIRE
Fujirebio Expands Its Alzheimer’s Disease Test Menu
22 Dec 2023 //
BUSINESSWIRE
Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials
14 Dec 2023 //
BUSINESSWIRE
Fujirebio and Sysmex Expand CDMO Partnership
30 Nov 2023 //
BUSINESSWIRE
Fujirebio and Sysmex Enter into Basic Agreement
10 Oct 2023 //
BUSINESSWIRE
AriBio and Fujirebio Announce Partnership to Advance Biomarker Development
08 Mar 2023 //
BUSINESSWIRE
Lumipulse G ?-Amyloid Ratio In Vitro Test Nabs Marketing Authorization
05 May 2022 //
BUSINESSWIRE
Fujirebio Confirms Engagement in Blood-based AD Biomarker Testing
30 Mar 2022 //
BUSINESSWIRE
Fujirebio Confirms Engagement in New Pathways for Alzheimer’s Disease Research
19 Nov 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.